Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about ...

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market ... to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development ...

Integrated Ventures Inc. ("Company") is pleased to announce the formation and launch of MedWell Facilities, LLC, a facilities management company dedicated to the health and wellness industry. In ...